Grifols clinical trials

The registry lists 108 studies whose lead sponsor is Grifols or one of 8 companies grouped under it. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 108. Browse all 108 →

• A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)RecruitingNCT07555483Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT07540221Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaRecruitingNCT07582432Phase 3

  Sponsor listed in the registry: Grifols Biologicals, LLC · First submitted after Grifols Biologicals, LLC became part of Grifols

• A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus InfectionRecruitingNCT07024641Phase 1

  Sponsor listed in the registry: GigaGen, Inc. · First submitted after GigaGen, Inc. became part of Grifols

• Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)RecruitingNCT05722938Phase 3

  Sponsor listed in the registry: Biotest · First submitted after Biotest became part of Grifols

• Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyEnrolling by invitationNCT02796937Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT06258304Phase 1

  Sponsor listed in the registry: GigaGen, Inc. · First submitted after GigaGen, Inc. became part of Grifols

• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT04722887Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety, Pharmacokinetics and Efficacy of an ATIII ConcentrateTerminatedNCT00319228Phase 2/3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)CompletedNCT01983241Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand PatientsTerminatedNCT00555555Phase 4

  Sponsor listed in the registry: Grifols Biologicals, LLC · First submitted after Grifols Biologicals, LLC became part of Grifols

• Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).CompletedNCT07264517Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%TerminatedNCT03702920Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand DiseaseWithdrawnNCT02472665Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-ADCompletedNCT03461276Phase 2

  Sponsor listed in the registry: Araclon Biotech S.L. · First submitted after Araclon Biotech S.L. became part of Grifols

• Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio SyndromeTerminatedNCT02176863Phase 2/3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyCompletedNCT02065882Phase 3

  Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols

• Adjusted Fibrinogen Replacement StrategyCompletedNCT03444324Phase 3

  Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols

• Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 PneumoniaTerminatedNCT05531149Phase 3

  Sponsor listed in the registry: Biotest · First submitted after Biotest became part of Grifols

• Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesCompletedNCT03451292Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)TerminatedNCT05170269Phase 3

  Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols

• Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia ACompletedNCT00323856Phase 4

  Sponsor listed in the registry: Grifols Biologicals, LLC · First submitted after Grifols Biologicals, LLC became part of Grifols

• A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee ArthroplastyCompletedNCT03981419Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols

• A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)TerminatedNCT05038020Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted after Alkahest, Inc. became part of Grifols

• FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical ProphylaxisWithdrawnNCT04636268Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyCompletedNCT04566692Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on HemodialysisCompletedNCT04985383Not applicable

  Sponsor listed in the registry: Alkahest, Inc. · First submitted after Alkahest, Inc. became part of Grifols

• A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous PemphigoidTerminatedNCT04499235Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols

• Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PIDCompletedNCT02810444Phase 3

  Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols

• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyCompletedNCT04561115Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric ParticipantsCompletedNCT03461406Phase 3

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)TerminatedNCT04547140Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19CompletedNCT04576728Phase 2

  Sponsor listed in the registry: Biotest · First submitted before Biotest became part of Grifols

• A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive ImpairmentCompletedNCT04527328Not applicable

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols

• A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory OutpatientsTerminatedNCT04847141Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMDCompletedNCT04331730Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols

• Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentCompletedNCT04369430Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols

• Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)CompletedNCT04480424Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentCompletedNCT03713957Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols

• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)CompletedNCT02870348Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaCompletedNCT02281500Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 PatientsTerminatedNCT04883138Phase 1

  Sponsor listed in the registry: GigaGen, Inc. · First submitted after GigaGen, Inc. became part of Grifols

• Alphanate in Immune Tolerance Induction TherapyTerminatedNCT03095287Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT02870309Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19CompletedNCT04495101Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral SclerosisCompletedNCT02872142Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)CompletedNCT04432324Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)CompletedNCT04547127Phase 2

  Sponsor listed in the registry: Instituto Grifols, S.A.

• A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT03520998Phase 2

  Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols